|
1
|
Khan SA, Davidson BR, Goldin R, et al:
Consensus document. Gut. 51 (Suppl 6):VI1–VI9. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gores GJ: A spotlight on
cholangiocarcinoma. Gastroenterology. 125:1536–1538. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao P, Lu Y, Zhong M, Liu L and Li B:
Inverse correlation of aberrant expression of fragile histidine
triad (FHIT) protein with cyclin D1 protein and prognosis in
Chinese patients with cholangiocarcinoma. Acta Oncol. 47:1557–1563.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heron DE, Stein DE, Eschelman DJ, et al:
Cholangiocarcinoma: The impact of tumor location and treatment
strategy on outcome. Am J Clin Oncol. 26:422–428. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu ZF, Wu XY, Zhu N, et al: Prognosis
after resection for hepatitis B virus-associated intrahepatic
cholangiocarcinoma. World J Gastroenterol. 21:935–943.
2015.PubMed/NCBI
|
|
6
|
Berman DM, Karhadkar SS, Maitra A, et al:
Widespread requirement for Hedgehog ligand stimulation in growth of
digestive tract tumors. Nature. 425:846–851. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Haslam RJ, Koide HB and Hemmings BA:
Pleckstrin domain homology. Nature. 363:309–310. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ingley E and Hemmings BA: Pleckstrin
homology (PH) domains in signal transduction. J Cell Biochem.
56:436–443. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saraste M and Hyvonen M: Pleckstrin
homology domains: A fact file. Curr Opin Struct Biol. 5:403–408.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nagai MA, Fregnani JH, Netto MM, et al:
Down-regulation of PHLDA1 gene expression is associated with breast
cancer progression. Breast Cancer Res Treat. 106:49–56. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neef R, Kuske MA, Pröls E and Johnson JP:
Identification of the human PHLDA1/TDAG51 gene: Down-regulation in
metastatic melanoma contributes to apoptosis resistance and growth
deregulation. Cancer Res. 62:5920–5929. 2002.PubMed/NCBI
|
|
12
|
Park CG, Lee SY, Kandala G, Lee SY and
Choi Y: A novel gene product that couples TCR signaling to Fas
(CD95) expression in activation-induced cell death. Immunity.
4:583–591. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hossain GS, van Thienen JV, Werstuck GH,
et al: TDAG51 is induced by homocysteine, promotes
detachment-mediated programmed cell death and contributes to the
development of atherosclerosis in hyperhomocysteinemia. J Biol
Chem. 278:30317–30327. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hayashida N, Inouye S, Fujimoto M, et al:
A novel HSF1-mediated death pathway that is suppressed by heat
shock proteins. EMBO J. 25:4773–4783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oberst MD, Beberman SJ, Zhao L, et al:
TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C
mammary epithelial cell transformation. BMC Cancer. 8:1892008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Toyoshima Y, Karas M, Yakar S, Dupont J,
et al: TDAG51 mediates the effects of insulin-like growth factor I
(IGF-I) on cell survival. J Biol Chem. 279:25898–25904. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sakthianandeswaren A, Christie M,
D'Andreti C, et al: PHLDA1 expression marks the putative epithelial
stem cells and contributes to intestinal tumorigenesis. Cancer Res.
71:3709–3719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sellheyer K and Nelson P: Follicular stem
cell marker PHLDA1 (TDAG51) is superior to cytokeratin-20 in
differentiating between trichoepithelioma and basal cell carcinoma
in small biopsy specimens. J Cutan Pathol. 38:542–550. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnson EO, Chang KH, Pablo Y, et al:
PHLDA1 is a crucial negative regulator and effector of aurora A
kinase in breast cancer. J Cell Sci. 124:2711–2722. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen YC, Hu FC, Jeng YM, et al: Nuclear
overexpression of mitotic regulatory proteins in biliary tract
cancer: Correlation with clinicopathologic features and patient
survival. Cancer Epidemiol Biomarkers Prev. 18:417–423. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hao XP, Willis JE, Pretlow TG, et al: Loss
of fragile histidine triad expression in colorectal carcinomas and
premalignant lesions. Cancer Res. 60:18–21. 2000.PubMed/NCBI
|
|
22
|
Alba MM, Santibáñez-Koref MF and Hancock
JM: The comparative genomics of polyglutamine repeats: Extreme
differences in the codon organization of repeat-encoding regions
between mammals and Drosophila. J Mol Evol. 52:249–259.
2001.PubMed/NCBI
|
|
23
|
Coutinho-Camillo CM, Lourenço SV, Nonogaki
S, Vartanian JG, Nagai MA, Kowalski LP and Soares FA: Expression of
PAR-4 and PHLDA1 is prognostic for overall and disease-free
survival in oral squamous cell carcinomas. Virchows Arch.
463:31–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miraglia S, Godfrey W, Yin AH, Atkins K,
Warnke R, Holden JT, Bray RA, Waller EK and Buck DW: A novel
five-transmembrane hematopoietic stem cell antigen: Isolation,
characterization and molecular cloning. Blood. 90:5013–5021.
1997.PubMed/NCBI
|
|
25
|
Yin AH, Miraglia S, Zanjani ED, et al:
AC133, a novel marker for human hematopoietic stem and progenitor
cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
|
|
26
|
Shmelkov SV, St Clair R, Lyden D and Rafii
S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 37:715–719.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shimada M, Sugimoto K, Iwahashi S, et al:
CD133 expression is a potential prognostic indicator in
intrahepatic cholangiocarcinoma. J Gastroenterol. 45:896–902. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leelawat K, Thongtawee T, Narong S, et al:
Strong expression of CD133 is associated with increased
cholangiocarcinoma progression. World J Gastroenterol.
17:1192–1198. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fan L, He F, Liu H, et al: CD133: A
potential indicator for differentiation and prognosis of human
cholangiocarcinoma. BMC Cancer. 11:3202011. View Article : Google Scholar : PubMed/NCBI
|
